Compare LSAK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LSAK | ANL |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | South Africa | Cayman Islands |
| Employees | N/A | 123 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 406.5M |
| IPO Year | 2005 | 2022 |
| Metric | LSAK | ANL |
|---|---|---|
| Price | $4.92 | $7.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 95.8K | ★ 168.9K |
| Earning Date | 05-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,701,000.00 | N/A |
| Revenue This Year | $14.35 | N/A |
| Revenue Next Year | $8.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $3.40 | $0.88 |
| 52 Week High | $5.54 | $12.09 |
| Indicator | LSAK | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 53.92 |
| Support Level | $4.38 | $7.21 |
| Resistance Level | $5.54 | $9.98 |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 30.12 | 63.99 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.